share_log

Stifel Maintains Hold on Deciphera Pharmaceuticals, Raises Price Target to $18

Stifel Maintains Hold on Deciphera Pharmaceuticals, Raises Price Target to $18

Stifel維持對Deciphera Pharmicals的控股,將目標股價提高至18美元
Benzinga Real-time News ·  2022/09/27 07:02

Stifel analyst Bradley Canino maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Hold and raises the price target from $11 to $18.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論